FMP
Eloxx Pharmaceuticals, Inc.
ELOX
OTC
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
0.0001 USD
3.0000000015651188e-12 (0.000003%)
Operating Data
Year
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Revenue
-
-
-
-
-
-
-
-
-
-
Revenue %
-
-
-
-
-
-
-
-
-
Ebitda
-46.15M
-50.55M
-33.45M
-66.02M
-33.37M
-
-
-
-
-
Ebitda %
100
100
100
100
100
100
100
100
100
Ebit
-46.37M
-51.11M
-34.03M
-66.98M
-34.07M
-
-
-
-
-
Ebit %
100
100
100
100
100
100
100
100
100
Depreciation
216k
559k
571k
960k
695k
-
-
-
-
-
Depreciation %
100
100
100
100
100
100
100
100
100
Balance Sheet
Year
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Total Cash
48.61M
56.28M
24.67M
42.27M
19.21M
-
-
-
-
-
Total Cash %
100
100
100
100
100
100
100
100
100
Receivables
-
26k
-
-
-
-
-
-
-
-
Receivables %
100
100
100
100
100
100
100
100
100
Inventories
-
708k
-
-
-
-
-
-
-
-
Inventories %
100
100
100
100
100
100
100
100
100
Payable
747k
1.87M
481k
1.38M
3.02M
-
-
-
-
-
Payable %
100
100
100
100
100
100
100
100
100
Cap Ex
-235k
-40k
-
-89k
-66k
-
-
-
-
-
Cap Ex %
100
100
100
100
100
-
-
-
-
Weighted Average Cost Of Capital
Price
0
Beta
Diluted Shares Outstanding
2.17M
Costof Debt
14.56
Tax Rate
After Tax Cost Of Debt
14.56
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
13.38M
Total Equity
216.63
Total Capital
13.38M
Debt Weighting
100
Equity Weighting
0
Wacc
14.56
Build Up Free Cash Flow
Year
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Revenue
-
-
-
-
-
-
-
-
-
-
Ebitda
-46.15M
-50.55M
-33.45M
-66.02M
-33.37M
-
-
-
-
-
Ebit
-46.37M
-51.11M
-34.03M
-66.98M
-34.07M
-
-
-
-
-
Tax Rate
-
-
-
-
-
-
-
-
-
-
Ebiat
-46.49M
-51.11M
-34.03M
-66.98M
-34.07M
-
-
-
-
-
Depreciation
216k
559k
571k
960k
695k
-
-
-
-
-
Receivables
-
26k
-
-
-
-
-
-
-
-
Inventories
-
708k
-
-
-
-
-
-
-
-
Payable
747k
1.87M
481k
1.38M
3.02M
-
-
-
-
-
Cap Ex
-235k
-40k
-
-89k
-66k
-
-
-
-
-
Ufcf
-45.76M
-50.2M
-34.11M
-65.21M
-31.8M
-3.02M
-
-
-
-
Wacc
14.56
14.56
14.56
14.56
14.56
Pv Ufcf
-2.64M
0
0
0
0
Sum Pv Ufcf
-2.64M
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
14.56
Free Cash Flow T1
0
Terminal Value
0
Present Terminal Value
0
Intrinsic Value
Enterprise Value
-2.64M
Net Debt
-5.82M
Equity Value
3.19M
Diluted Shares Outstanding
2.17M
Equity Value Per Share
1.47
Projected DCF
1.47 1%
